Alpha-1 Antitrypsin Deficiency Disease Market Size, Share & Trends Analysis Report By Product (Alpha-1 Proteinase Inhibitor, Bronchodilators), By Route Of Administration, By End-user, By Region, and Segment Forecasts, 2023 To 2030

The generation of alpha-1 antitrypsin (AAT) protein in the liver is impacted by alpha-1 antitrypsin deficiency (AATD), a hereditary condition. The lungs' defense against harm from enzymes generated during inflammation is provided by AAT. Lung and liver disorders can result from low amounts or malfunctioning AAT protein in AATD. Alpha-1 antitrypsin (AAT), a protein that is produced as a result of instructions provided by the SERPINA1 gene, is the cause of the condition. Chronic obstructive pulmonary disease (COPD) and emphysema are among the lung conditions that are the main symptoms of AATD. Due to neutrophil elastase's unchecked activity, these disorders are brought on by the progressive degeneration of lung tissue. Breathlessness, coughing, wheezing, and recurrent respiratory infections are some of the signs of lung illness linked to AATD.

The growth of the market is attributed to rising public and professional awareness of the disease, availability of sophisticated genetic testing methods, and ongoing research and development initiatives to create novel treatments. For instance, in May 2023, Glassia's Swiss commercial approval for the therapeutic use of alpha-1 antitrypsin deficiency was announced by Kamada Pharmaceuticals. Glassia [Alpha-1 Proteinase Inhibitor (Human)] has been given marketing approval by Swissmedic for prolonged augmentation and maintenance therapy in persons with clinically obvious emphysema caused by severe familial alpha-1 antitrypsin deficiency disease.

Moreover, the regulatory approval by various government agencies for novel therapies and product launches are expected to accelerate the market. For instance, in March 2023, Mereo BioPharma Group plc received a positive feedback for its alvelestat program from FDA and EMA for the treatment of alpha-1-antitrypsin deficiency-associated with lung disease. Also, in March 2022, Inhibrx, Inc. received fast track designation for its INBRX-101, which is clinical trials for the treatment of alpha-1 antitrypsin deficiency.

North America is estimated to dominate the alpha-1 antitrypsin deficiency disease market due to a strong healthcare infrastructure, presence of significant market competitors, continuous research and development initiatives, and advantageous reimbursement policies. The Asia Pacific alpha-1 antitrypsin deficiency disease market is also expected to register substantial CAGR owing to expanding healthcare infrastructure, rising awareness regarding rare diseases, and increasing number of investments for disease research. The market's expansion in this area is projected to be driven by nations like China, Japan, and India.

Major companies operating in the market include Shire plc, GlaxoSmithKline plc, CSL Behring, AstraZeneca Plc., Grifols S.A., Teva Pharmaceutical Industries, Boehringer Ingelheim International GmbH, Kamada Pharmaceuticals, Pfizer Inc., Baxter International Inc., AstraZeneca Plc., Boehringer Ingelheim International GmbH. These players are focusing implementation of organic and in-organic strategies to consolidate their position in the market. For instance, in March 2023, Gain Therapeutics received grant of USD 1.3 million from Eurostars for its AAT deficiency treatment research program.